KALA BIO, Inc. — Director's Dealing 2017

Jul 19, 2017

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Kala Pharmaceuticals, Inc. (KALA)
CIK: 0001479419
Period of Report: 2017-07-19

Reporting Person: Rosen Howard B (Director)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	3240	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$0.47	2021-06-16	Common Stock (1944)		Direct
Stock Option (right to buy)	$0.68	2023-05-10	Common Stock (2880)		Direct
Stock Option (right to buy)	$2.30	2024-10-02	Common Stock (38246)		Direct

Footnotes

F1: This option is fully vested.

F2: This option is fully vested.

F3: This option was granted on October 2, 2014 and vests over four years, with 2.0833% of the shares underlying the option vested on February 28, 2014 and an additional 2.0833% vesting at the end of each successive one-month period thereafter.